In summary, avapritinib represents a transformative advancement in the management of GIST—especially for patients with imatinib-resistant mutations such as PDGFRA D842V—offering both improved clinical outcomes and a tolerable side effect profile. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.